Search
Naxitamab
go.drugbank.com/drugs/DB15965ApprovedInvestigational[A224474] One stark disadvantage of this therapy is the requirement for concurrent use of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA). … [L24454] This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies,[A224604] making
Aminohippuric acid
go.drugbank.com/drugs/DB00345ApprovedInvestigationalWithdrawnThe glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]
Categories: Compounds used in a research, industrial, or household settingSynonyms: N-(p-Aminobenzoyl)glycine, N-(p-Aminobenzoyl)aminoacetic acidAducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigationalAducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-β plaques in the brain; similar to [gantenerumab], [bapineuzumab] and [solanezumab]. … [L34420] Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard
Ziconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigational[L13389] To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.[A202835] … [A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.
Categories: Calcium Channels, N-Type, N-Calcium Channel Receptor AntagonistsOmidubicel
go.drugbank.com/drugs/DB17132ApprovedInvestigationalUmbilical blood cord cells are expanded _ex-vivo_ and [nicotinamide] (a form of vitamin B3) is used as an active agent in the culture system to inhibit the differentiation and increase the functionality … It is administered as a single intravenous dose specific to each patient.
Protein C
go.drugbank.com/drugs/DB11312ApprovedInvestigationalOnce in its activated form, APC functions as a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S. … It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC).
Mixtures: Beriplex P/n 500, Beriplex P/n 1000Categories: protein CSamidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigational[A235638, A235643] Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™ … may be expected to ameliorate these negative effects.
Salts: Samidorphan L-malateCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesVericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigational[A227458] As a direct stimulator of sGC, vericiguat mitigates the need for a functional NO-sGC-cGMP axis and thereby helps to prevent the myocardial and vascular dysfunction associated with decreased sGC … Vericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and hospitalizations.
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingProducts: VERQUVO® 5MG TABLETAS RECUBIERTAS, VERQUVO® 10MG TABLETAS RECUBIERTASDaclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnIt is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydrochloride salt form . … The therapy is intended to cure or achieve a sustained virologic response (SVR12), after 12 weeks of daily therapy.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: I-HEP CLASTAVIR 30, I-HEP CLASTAVIR 60Gelatin
go.drugbank.com/drugs/DB11242ApprovedInvestigationalVet approvedWithdrawn[A32426] Gelatin is generally recognized as safe (GRAS) by the FDA to be a non-hazardous food or food ingredient. … [L2110] The FDA withdrew its approval for the use of all intravenous drug products containing gelatin. Gelatin continues to be approved for other routes of administration.[L43942]
Mixtures: GELOFUSINE® ISO 4%Products: INFUSOL SG (SUCCINYLATED GELATIN (Bovine) INTRAVENOUS INFUSION 4% w/v), GELAFUNDIN 4